Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

Figures & data

Table 1 General Data of Patients in Two Groups [n(%)] (Mean±SD)

Categories	Research Group (n=48)	Control Group (n=48)	t/χ^2	P
Average age (years)	50.16±5.27	50.39±5.34	0.212	0.832
BMI (kg/m2)	22.43±3.12	22.85±3.17	0.654	0.515
Residence			1.046	0.307
Urban	28 (58.33)	23 (47.92)
Rural	20 (41.67)	25 (52.08)
Ethnicity			1.688	0.194
Han	35 (72.92)	29 (60.42)
Ethnic minorities	13 (27.08)	19 (39.58)
Educational background			0.667	0.414
≥High school	22 (45.83)	26 (54.17)
<High school	26 (54.17)	22 (45.83)
Tumor type			0.488	0.922
Invasive ductal carcinoma	24 (50.00)	27 (56.25)
Invasive lobular carcinoma	19 (39.58)	17 (35.42)
Inflammatory breast cancer	2 (4.17)	2 (4.17)
Medullary carcinoma	3 (6.25)	2 (4.17)
TNM staging			0.274	0.872
IIIa	18 (37.50)	19 (39.58)
IIIb	20 (41.67)	21 (43.75)
IV	10 (20.83)	8 (16.67)
History of smoking			0.668	0.414
Yes	27 (56.25)	23 (47.92)
No	21 (43.75)	25 (52.08)
History of drinking			0.389	0.533
Yes	30 (62.50)	27 (56.25)
No	18 (37.50)	21 (43.75)

Figure 1 Comparison of serum tumor markers between two groups before and after treatment. (A) There was no difference in CEA expression between the two groups before treatment, but CEA in the research group was significantly lower than that in the control group after treatment. (B) There was no difference in CA125 expression between the two groups before treatment, but CA125 in the research group was significantly lower than that in the control group after treatment. (C) There was no difference in CA15-3 expression between the two groups before treatment, but CA15-3 expression in the research group was significantly lower than that in the control group after treatment.

Note: ***Indicates P<0.001.

Figure 2 Comparison of inflammatory factors between two groups before and after treatment. (A) There was no difference in CRP expression between the two groups before treatment, but CRP in the research group was significantly lower than that in the control group after treatment. (B) There was no difference in TNF-α expression between the two groups before treatment, but TNF-α expression in the research group was significantly lower than that in the control group after treatment.

Note: ***Indicates P<0.001.

Table 2 Comparison of Curative Effects Between Two Groups After Treatment [n(%)]

Groups	n	CR	PR	SD	PD	Total Effective Rate (%)
Research group	48	6 (12.50)	36 (75.00)	4 (8.33)	2 (4.17)	42 (87.50)
Control group	48	4 (8.33)	29 (60.42)	7 (14.58)	8 (16.67)	33 (68.75)
χ^2	–	–	–	–	–	4.937
P	–	–	–	–	–	0.026

Table 3 Incidence of Adverse Reactions in Two Groups During Treatment [n(%)]

Groups	n	Grade III–IV Myelosuppression	Grade III–IV Gastrointestinal Reaction	Nausea and Vomiting	Liver Function Damage	Cardiotoxicity	Peripheral Neurotoxicity	Total Incidence (%)
Research group	48	3 (6.25)	2 (4.17)	2 (4.17)	1 (2.08)	1 (2.08)	1 (2.08)	10 (20.83)
Control group	48	4 (8.33)	3 (6.25)	3 (6.25)	2 (4.17)	0 (0.00)	0 (0.00)	12 (25.00)
χ^2	–	0.154	0.221	0.221	0.344	1.011	1.011	0.236
P	–	0.695	0.646	0.646	0.558	0.315	0.315	0.627

Table 4 Comparison of Quality of Life Scores Between Two Groups Before and After Treatment (Mean±SD)

Groups	n	KPS Score
		Before Treatment	After Treatment
Research group	48	77.62±5.29	91.05±8.22
Control group	48	76.89±6.47	84.64±7.12
t	–	0.605	4.084
P	–	0.547	<0.001

Table 5 Variable Assignment Table of Unconditional Logistic Regression Analysis

Factor	Variable	Assignment
CEA	X1	Continuous variable
CA125	X2	Continuous variable
CA15-3	X3	Continuous variable
CRP	X4	Continuous variable
TNF-α	X5	Continuous variable
KPS score	X6	Continuous variable
Therapy	X7	0 = docetaxel, 1 = trastuzumab combined with docetaxel

Table 6 Multivariate Analysis of Factors Influencing the Curative Effect of Patients with HER-2+ Breast Cancer

Factor	P	OR	95% CI
CEA	0.015	1.638	1.105–2.433
CA125	0.014	1.208	0.457–0.998
CA15-3	0.008	1.135	0.924–1.458
CRP	0.434	0.985	0.935–1.094
TNF-α	0.376	0.989	0.967–1.014
KPS score	0.520	1.039	0.924–1.169
Docetaxel monotherapy	0.001	2.172	1.785–2.634